Of note, NSCLC patients with TP53-mutant tumors, especially in exons 6 and 7, were significantly associated with inferior PFS and OS, compared to EGFR-positive patients with TP53-wild type tumors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.